These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 23178991)
1. IBS and the role of otilonium bromide. Boeckxstaens G; Corazziari ES; Mearin F; Tack J Int J Colorectal Dis; 2013 Mar; 28(3):295-304. PubMed ID: 23178991 [TBL] [Abstract][Full Text] [Related]
2. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545 [TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J; Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214 [TBL] [Abstract][Full Text] [Related]
4. Irritable bowel syndrome. Spinelli A Clin Drug Investig; 2007; 27(1):15-33. PubMed ID: 17177577 [TBL] [Abstract][Full Text] [Related]
6. Role of antispasmodics in the treatment of irritable bowel syndrome. Annaházi A; Róka R; Rosztóczy A; Wittmann T World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726 [TBL] [Abstract][Full Text] [Related]
7. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial. Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484 [TBL] [Abstract][Full Text] [Related]
8. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Evangelista S Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053 [TBL] [Abstract][Full Text] [Related]
10. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Glende M; Morselli-Labate AM; Battaglia G; Evangelista S Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954 [TBL] [Abstract][Full Text] [Related]
11. Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model. Traini C; Idrizaj E; Garella R; Faussone-Pellegrini MS; Baccari MC; Vannucchi MG J Cell Mol Med; 2021 Jul; 25(14):6988-7000. PubMed ID: 34109728 [TBL] [Abstract][Full Text] [Related]
12. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related]
13. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Battaglia G; Morselli-Labate AM; Camarri E; Francavilla A; De Marco F; Mastropaolo G; Naccarato R Aliment Pharmacol Ther; 1998 Oct; 12(10):1003-10. PubMed ID: 9798806 [TBL] [Abstract][Full Text] [Related]
19. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Liu R; Staller K Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371 [TBL] [Abstract][Full Text] [Related]
20. Tegaserod for the treatment of irritable bowel syndrome. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]